Skip to content
DeepViews

Glaukos Corporation (GKOS) — 分析摘要

Glaukos Corporation(GKOS)的市值为9.91十亿美元,最近一年的营收同比增长了+32.3%。净利润率为-37.0%。当前市盈率为-52.7倍。

核心要点

  • 营收同比变化+32.3%
  • 净利润率-37.0%
  • 市盈率-52.7倍

与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比,GKOS的营收增长为+32.3%,市盈率为-52.7倍。

[XNYS]

Glaukos Corporation (GKOS)

$168.02

前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$9910.48M
企业价值
$9796.00M
市盈率
-52.7
股息率
0.00%
EV/EBITDA
-64.7
公司简介
关于
关于 Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

行业

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

员工人数

1,094

总部

ALISO VIEJO, CA

Exchange

XNYS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
46
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$682.49M
总债务$0.00M
债务权益比0.00
现金及等价物$114.48M

现金流

经营现金流$-0.95M
自由现金流$-12.20M
自由现金流率-1.99%
P/FCF 比率-812.60
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。